We focused on p53 mutations, which are highly implicated in pancreatic ductal adenocarcinoma (PDAC), and PD-L1, a biomarker for immune checkpoint inhibitor-based therapies. The gene discussed is TP53; the disease is pancreatic ductal adenocarcinoma.